Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company’s transformation and growth in autoimmune disease CAMBRIDGE, Mass., July ...
-- 64% identify AI and machine learning as top technology investment priorities for 2026, up from 43% in 2025. -- Only 15% of organizations report being well or fully prepared to support advanced ...
CAMBRIDGE, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results